FGFR2 and cholangiocarcinoma: IDH1 (approximately 13% identified in CCAs), FGFR2 (about 20% detected), NTRK (<1%), TMB, MSI/MMR (2–3%), KRAS, TP53, BRCA 1/2 (about 1–7%), BRAF, CDKN2A/B, BAP1, PIK3CA, and HER2 are potential and promising mutation profiles, which may direct the CCA targeted therapy [9–11].